- Investing Ideas
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
Results
22
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
22 companies
Alkermes
Market Cap: US$8.5b
A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
ALKS
US$48.34
7D
-8.1%
1Y
73.1%
Praxis Precision Medicines
Market Cap: US$8.1b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$291.03
7D
-9.7%
1Y
436.8%
ImmunityBio
Market Cap: US$7.3b
A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
IBRX
US$6.83
7D
-9.1%
1Y
166.8%
Erasca
Market Cap: US$6.3b
A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
ERAS
US$17.72
7D
-9.2%
1Y
1,043.2%
Twist Bioscience
Market Cap: US$5.5b
Manufactures and sells synthetic DNA-based products.
TWST
US$85.47
7D
-9.3%
1Y
146.1%
Tango Therapeutics
Market Cap: US$3.9b
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
TNGX
US$25.85
7D
-8.0%
1Y
310.3%
Arcus Biosciences
Market Cap: US$3.4b
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$26.45
7D
-11.7%
1Y
180.5%
Vera Therapeutics
Market Cap: US$2.3b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$32.51
7D
-10.6%
1Y
56.4%
Iovance Biotherapeutics
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
IOVA
US$4.56
7D
-11.8%
1Y
70.8%
Syndax Pharmaceuticals
Market Cap: US$1.7b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.22
7D
-9.4%
1Y
93.8%
COMPASS Pathways
Market Cap: US$1.5b
Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
CMPS
US$10.90
7D
-8.6%
1Y
176.6%
Cryoport
Market Cap: US$764.6m
Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
CYRX
US$14.93
7D
-9.1%
1Y
98.0%
Ironwood Pharmaceuticals
Market Cap: US$625.5m
A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
IRWD
US$3.56
7D
-8.2%
1Y
327.3%
Immix Biopharma
Market Cap: US$600.8m
A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
IMMX
US$8.17
7D
-13.2%
1Y
197.1%
4D Molecular Therapeutics
Market Cap: US$514.9m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$9.61
7D
-12.3%
1Y
117.9%
MacroGenics
Market Cap: US$244.7m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
MGNX
US$3.67
7D
-14.7%
1Y
138.3%
Whitehawk Therapeutics
Market Cap: US$197.9m
A clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
WHWK
US$3.66
7D
-8.3%
1Y
104.5%
Immunic
Market Cap: US$181.7m
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
IMUX
US$13.05
7D
-13.6%
1Y
35.7%
Equillium
Market Cap: US$146.7m
A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
EQ
US$2.28
7D
-17.4%
1Y
492.8%
Kazia Therapeutics
Market Cap: US$145.0m
Operates as an oncology-focused biotechnology company in Israel.
KZIA
US$12.03
7D
-17.6%
1Y
42.1%
Clene
Market Cap: US$63.8m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$4.72
7D
-18.9%
1Y
35.2%
Polyrizon
Market Cap: US$21.1m
A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
PLRZ
US$11.70
7D
-18.7%
1Y
54.8%